Skip Trinity Banner Navigation

Skip to main content »

Trinity College Dublin

Personal Information
College Photo Name Norris, Lucy Angela
Main Department Obstetrics
College Title SENIOR EXP OFFICER OBS&GYN (P/T 17/8/06)
E-mail lnorris@tcd.ie
College Tel +353 1 896 2116
Web http://people.tcd.ie/lnorris
Fax +353 1 453 1614
 
Biography
Lucy Norris graduated from Trinity College Dublin with an honours degree in Biochemistry. She was awarded a PhD in 1992 from TCD Dept of Obstetrics and Gynaecology based on her work investigating platelet activation in pregnancy, pre-eclampsia and oral contraception. She was PI on several large scale studies investigating the mechanisms of haemostatic activation in hormone users (OC and HRT) collaborating with key figures in the field in Europe and North America and writing two consensus documents in this area. In 2002, she was awarded an MSc in Molecular Medicine from TCD and following this has established a group investigating the molecular effects of hormones on coagulation gene expression funded by the Health Research Board. Lucy’s interests also extend to pregnancy where, in collaboration with Prof John Higgins in UCC, she is currently investigating new biomarkers to predict venous thrombosis in pregnancy and also the effects of LMWH on thrombin production in high risk pregnancy groups such as the obese. In collaboration with Dr. Noreen Gleeson and Prof. John O’Leary, her research programme has also extended to gynaecological cancers; the role of coagulation gene expression in the aetiology of ovarian cancer and in prediction of venous thrombosis post gynaecological surgery is currently being investigated (funded by the HRB). She has over 60 peer reviewed publications, many as senior author, including 5 invited reviews. She is a member of the International Society for Thrombosis and Haemostasis and is a member of the editorial board for the journal ‘Thrombosis Research’.
 
Representations
Details Date
Member of the Editorial board of Thrombosis Research
 
Membership of Professional Institutions, Associations, Societies
Details Date From Date To
Member of International Society for Thrombosis and Haemostasis
 
Awards and Honours
Award Date
Royal Academy of Medicine Donegan medal 2nd prize 1987
 
Languages
Language Skill Reading Skill Writing Skill Speaking
English Fluent Fluent Fluent
 
Description of Research Interests
The role of coagulation proteases and platelets in the aetiology of gynaecological cancers. Development of risk models for the prediction of thrombosis in gynaecological cancer patients. Aetiology of thrombosis risk in high risk pregnancy patients. Effects of oestrogens, progestogens and phytoestogens on coagulation gene expression and their role in thrombosis risk. The role of coagulation gene expression in the transition from endometriosis to clear cell cancer.
 
Research Interests
Biomedical sciences Cardiovascular risk assessment and hormone replacement therapy Clinical research, trials Coagulation biochemistry and disorders
Cytokines, Nitric Oxide Foetal, maternal and neonatal physiology Haemotology Hormone physiology and biochemistry
Inflammation and coagulation syndromes Medical Sciences, Research Menopause Molecular haematology
Oral contaraceptives and haemostasis Pre-eclampsia and intrauterine growth retardation Prevention, treatment of thromboembolic complications in pregnancy Reproduction, fertility and contraception
Thrombosis and haemostasis Vascular Biology, Thrombosis
 
Research Projects
Project title A risk model for prediction of venous thromboembolism in gynaecological cancer patients post surgery
Summary Venous thromboembolism (VTE) is a common cause of death in patients with solid tumours. Cancer itself causes a hypercoagulable state, in addition chemotherapy and surgery enhance the risk. Gynaecological cancers have been associated with high rates of VTE which is excacerbated by pelvic surgery and chemotherapy. A recent study in our centre showed that one third of VTE in ovarian cancer patients occurs within 5 days of surgery despite heparin prophylaxis. Recently, clinical risk models have been developed to predict VTE in patients undergoing chemotherapy, these models have been shown to be more powerful when combined with haemostatic biomarkers. Thrombus formation is complex in cancer and is thought to result from a release of procoagulant material from the tumour combined with damage to the endothelium as a result of chemotherapy and surgery. Global tests of hypercoagulability which capture these effects are therefore attractive as determinants of thrombotic risk. Calibrated automated thrombograpy (CAT) is a recently developed global test which measures thrombin generation in plasma. Increased thrombin generation is predictive of VTE in a variety of clinical settings. The overarching aim of this project is to develop and validate a specific risk scoring model for VTE risk in gynaecological cancer patients using a combination of easily available clinical and laboratory parameters and haemostatic biomarkers. In a large population of gynaecological cancer patients, we will identify the key risk factors for VTE and use them to derive a risk score model. Based on our pilot data, we believe that a thrombin generation test may be a useful biomarker for VTE in gynaecological cancer. By understanding the mechanisms by which gynaecological cancer increases procoagulant activity, we will optimise a specific thrombin generation assay which when combined with the derived risk score model will accurately identify gynaecological cancer patients at high risk of VTE.
Funding Agency HRB
Programme Project grant
Type of Project Principle Investigator
Date from 2013
Date to 2016
Person Months


Project title THE ROLE OF TISSUE FACTOR IN THE TRANSITION FROM ENDOMETRIOSIS TO CLEAR CELL CANCER OF THE OVARY
Summary Increased expression of both PAR-2 and TF in the eutopic and ectopic endometrium from women with endometriosis compared with normal women has been reported (Krikun et al,2008) however it is unknown whether a further increase in expression is implicated in malignant transformation of endometrioma into clear cell cancer. Our hypothesis is that expression and activation of the TF-VIIa-PAR-2 signalling pathway is further increased in clear cell cancers particularly those formed on a background of endometriosis and that this may provide a potential target for treatment of clear cell cancers. We also believe that TFPI-2 may be a useful diagnostic marker for clear cell cancers. The aim of the study is to compare the expression of TF, VIIa and PAR-2 in clear cell cancers with endometrial tissue from patients with endometriosis. A secondary aim is to investigate the role of serum TFPI-2 as a possible non invasive tool for distinguishing endometriosis from clear cell cancers.
Funding Agency Leo pharma
Programme Unrestricted educational grant
Type of Project [Co-applicant with Dr Noreen Gleeson]
Date from 2013
Date to 2015
Person Months


Project title Thromboelastography as a predictor of venous thrombosis in gynaecological oncology patients undergoing surgery.
Summary Ovarian cancer is associated with high rates of venous thromboembolism (VTE) particularly after surgery even in the setting of appropriate prophylaxis.The treatment and prevention of VTE is challenging in these patients after major surgery, as pelvic surgery itself is also an additional high risk factor for VTE. Thromboelastography(TEG) is a technique which allows rapid global assessment of haemostatic/fibrinolytic function and has been proposed as a marker of hypercoagulability in a variety of clinical settings. The aim of this study is to determine the level of hypercoagulability using TEG in patients undergoing major gynaecological surgery for suspected cancer, and to determine the potential of TEG as a predictor of VTE.
Funding Agency Gynaecological Cancer Fund, SJH
Programme
Type of Project [Co-applicant with Dr Noreen Gleeson]
Date from 2012
Date to 2015
Person Months


Project title Interrogation of the Onco-metabolome in ovarian cancer
Summary The metabolic syndrome is characterised by low-level inflammation, coagulation activation and increased risk of cancer. This study seeks to interrogate the inter-linked nature of these mechanisms in ovarian cancer. The association while present in ovarian cancer patients is not well defined. The aim of this study is to assess if platelet cloaking of CTCs in obese patients with ovarian cancer, due to increased systemic inflammation is a mechanism underlying worse prognosis in these patients.
Funding Agency Royal City of Dublin Hospital Trust
Programme Co-applicant with Dr. Sharon O'Toole and Prof John O'Leary
Type of Project
Date from 2013
Date to 2016
Person Months


Project title Endogenous thrombin potential (ETP) and microparticle tissue factor(TF) activity as markers of venous thromboembolism in gynaecological cancer patients.
Summary Increased Tissue Factor from tumour cells may cause an enhanced plasma procoagulant activity ultimately resulting in VTE. The majority of these patient would have major pelvic surgery as part of their treatment, with the risk of bleeding. Endogenous Thrombin Potential (ETP) assay is a new method which has shown potential as predictor of VTE risk. The aim of the study is to compare the procoagulant activity in plasma of patients with benign and malignant ovarian tumous using the ETP assay. and to compare the procoagulant activity levels in patients following neoadjuvant chemotherapy with those undergoing surgery for primary tumours
Funding Agency Leo Pharma IIS/Gynaecological Oncology Fund SJH
Programme Unrestricted educational grant (Leo)
Type of Project [Co-applicant with Dr Noreen Gleeson]
Date from 2010
Date to 2013
Person Months


More Research Projects>>>
 
Publications and Other Research Outputs
Peer Reviewed
Norris L A, Brosnan J, Bonnar J, Conard J, Kluft C, Hellgren M , INHIBITORS AND ACTIVATION MARKERS OF THE HAEMOSTATIC SYSTEM DURING HORMONE THERAPY: , Thrombosis and Haemostasis, 100, (2), 2008, p253 - 260
Brosnan JF, Sheppard BL, Norris LA, Haemostatic activation in post menopausal women taking low dose hormone therapy: less effect with transdermal administration?, Thrombosis and Haemostasis, 97, (4), 2007, p558 - 565
DOI
Norris LA, Bonnar J, Smith MP, Steer PJ, Savidge G, Low molecular weight heparin (tinzaparin) therapy for moderate risk thromboprophylaxis during pregnancy. A pharmacokinetic study, Thrombosis and Haemostasis, 92, (4), 2004, p791 - 796
Smith MP, Norris LA, Steer PJ, Savidge GF, Bonnar J, Tinzaparin sodium for thrombosis treatment and prevention during pregnancy., American Journal of Obstetrics and Gynaecology, 190, (4), 2004, p495 - 501
More Publications and Other Research Outputs >>>
 

Log in to the TCD Portal

Contact:helpdesk@tcd.ie
Last Updated:02-OCT-2014